74 related articles for article (PubMed ID: 23583449)
1. A crucial role for Lyn in TIMP-1 erythroid cell survival signalling pathway.
Bridoux L; Etique N; Lambert E; Thevenard J; Sowa ML; Belloy N; Dauchez M; Martiny L; Charpentier E
FEBS Lett; 2013 May; 587(10):1524-8. PubMed ID: 23583449
[TBL] [Abstract][Full Text] [Related]
2. Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn.
Tilbrook PA; Palmer GA; Bittorf T; McCarthy DJ; Wright MJ; Sarna MK; Linnekin D; Cull VS; Williams JH; Ingley E; Schneider-Mergener J; Krystal G; Klinken SP
Cancer Res; 2001 Mar; 61(6):2453-8. PubMed ID: 11289114
[TBL] [Abstract][Full Text] [Related]
3. Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival.
Lambert E; Boudot C; Kadri Z; Soula-Rothhut M; Sowa ML; Mayeux P; Hornebeck W; Haye B; Petitfrere E
Biochem J; 2003 Jun; 372(Pt 3):767-74. PubMed ID: 12639219
[TBL] [Abstract][Full Text] [Related]
4. TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival.
Lambert E; Bridoux L; Devy J; Dassé E; Sowa ML; Duca L; Hornebeck W; Martiny L; Petitfrère-Charpentier E
Int J Biochem Cell Biol; 2009 May; 41(5):1102-15. PubMed ID: 19010442
[TBL] [Abstract][Full Text] [Related]
5. Lyn kinase plays important roles in erythroid expansion, maturation and erythropoietin receptor signalling by regulating inhibitory signalling pathways that control survival.
Slavova-Azmanova NS; Kucera N; Louw A; Satiaputra J; Handoko A; Singer P; Stone L; McCarthy DJ; Klinken SP; Hibbs ML; Ingley E
Biochem J; 2014 May; 459(3):455-66. PubMed ID: 24552351
[TBL] [Abstract][Full Text] [Related]
6. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
7. A novel signaling pathway associated with Lyn, PI 3-kinase and Akt supports the proliferation of myeloma cells.
Iqbal MS; Tsuyama N; Obata M; Ishikawa H
Biochem Biophys Res Commun; 2010 Feb; 392(3):415-20. PubMed ID: 20079716
[TBL] [Abstract][Full Text] [Related]
8. Csk-binding protein controls red blood cell development via regulation of Lyn tyrosine kinase activity.
Plani-Lam JH; Slavova-Azmanova NS; Kucera N; Louw A; Satiaputra J; Singer P; Lam KP; Hibbs ML; Ingley E
Exp Hematol; 2017 Feb; 46():70-82.e10. PubMed ID: 27751872
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation.
Kadri Z; Maouche-Chretien L; Rooke HM; Orkin SH; Romeo PH; Mayeux P; Leboulch P; Chretien S
Mol Cell Biol; 2005 Sep; 25(17):7412-22. PubMed ID: 16107690
[TBL] [Abstract][Full Text] [Related]
10. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation.
Adachi T; Stafford S; Sur S; Alam R
J Immunol; 1999 Jul; 163(2):939-46. PubMed ID: 10395690
[TBL] [Abstract][Full Text] [Related]
11. The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling.
Forte D; Salvestrini V; Corradi G; Rossi L; Catani L; Lemoli RM; Cavo M; Curti A
Oncotarget; 2017 Jan; 8(2):2261-2274. PubMed ID: 27903985
[TBL] [Abstract][Full Text] [Related]
12. Ribosomal protein L11- and retinol dehydrogenase 11-induced erythroid proliferation without erythropoietin in UT-7/Epo erythroleukemic cells.
Kummalue T; Inoue T; Miura Y; Narusawa M; Inoue H; Komatsu N; Wanachiwanawin W; Sugiyama D; Tani K
Exp Hematol; 2015 May; 43(5):414-423.e1. PubMed ID: 25829192
[TBL] [Abstract][Full Text] [Related]
13. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.
Contri A; Brunati AM; Trentin L; Cabrelle A; Miorin M; Cesaro L; Pinna LA; Zambello R; Semenzato G; Donella-Deana A
J Clin Invest; 2005 Feb; 115(2):369-78. PubMed ID: 15650771
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
Gamas P; Marchetti S; Puissant A; Grosso S; Jacquel A; Colosetti P; Pasquet JM; Mahon FX; Cassuto JP; Auberger P
Leukemia; 2009 Aug; 23(8):1500-6. PubMed ID: 19340007
[TBL] [Abstract][Full Text] [Related]
15. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.
Bates RC; Edwards NS; Burns GF; Fisher DE
Cancer Res; 2001 Jul; 61(13):5275-83. PubMed ID: 11431370
[TBL] [Abstract][Full Text] [Related]
16. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
17. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.
ten Hacken E; Scielzo C; Bertilaccio MT; Scarfò L; Apollonio B; Barbaglio F; Stamatopoulos K; Ponzoni M; Ghia P; Caligaris-Cappio F
Blood; 2013 Mar; 121(12):2264-73. PubMed ID: 23325840
[TBL] [Abstract][Full Text] [Related]
18. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.
Okutani Y; Kitanaka A; Tanaka T; Kamano H; Ohnishi H; Kubota Y; Ishida T; Takahara J
Oncogene; 2001 Oct; 20(45):6643-50. PubMed ID: 11641791
[TBL] [Abstract][Full Text] [Related]
19. Exogenous tissue inhibitor of metalloproteinase-1 promotes endothelial cell survival through activation of the phosphatidylinositol 3-kinase/Akt pathway.
Boulday G; Fitau J; Coupel S; Soulillou JP; Charreau B
Ann N Y Acad Sci; 2004 Dec; 1030():28-36. PubMed ID: 15659777
[TBL] [Abstract][Full Text] [Related]
20. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
